09:09:46 EDT Wed 08 May 2024
Enter Symbol
or Name
USA
CA



Medwell Capital Corp (2)
Symbol MWC
Shares Issued 7,282,589
Close 2014-11-27 C$ 1.11
Market Cap C$ 8,083,674
Recent Sedar Documents

ORIGINAL: Medwell Capital loses $1.07-million in Q3 2014

2014-11-28 11:46 ET - News Release

Received by email:

File: Medwell Press Release 2014 Q3Final .docx

/




MEDWELL CAPITAL REPORTS Q3 RESULTS 

Edmonton, Alberta, November 28, 2014 - Medwell Capital Corp. (TSX-V: MWC) today announced its financial and operationa
--->l results for the quarter ended September 30, 2014.

Financial Results 

For the quarter ended September 30, 2014, the consolidated net loss of the Corporation was $1,078,000 ($0.14 per share
--->), as compared to a net income of $1,735,000 ($0.24 income per share) for the same period last year. The loss for the 
--->quarter largely reflects an unrealized loss of $697,000 on the Spectral investment.

The Company continues to manage costs judiciously and ended the quarter with $3.5 million in cash and cash equivalents
--->.

As at September 30, 2014, there were 7,282,589 common shares issued and outstanding.

For complete financial results, please see the company's filings at SEDAR or on the company's website (www.medwellcapi
--->tal.com).


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX 
--->Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.  This press release may contain
---> forward-looking statements, which reflect the Company's current expectation regarding future events.  These forward-l
--->ooking statements involve risks and uncertainties that may cause actual results, events or developments to be material
--->ly different from any future results, events or developments expressed or implied by such forward-looking statements. 
---> Such factors include, but are not limited to, changing market conditions, the successful and timely completion of cli
--->nical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product d
--->evelopment, uncertainties related to the regulatory approval process and other risks detailed from time to time in the
---> Corporation's ongoing quarterly and annual reporting.  We undertake no obligation to publicly update or revise any fo
--->rward-looking statements, whether as a result of new information, future events or otherwise. 



© 2024 Canjex Publishing Ltd. All rights reserved.